Navigation Links
Hepatitis C study shows superior viral cure rate
Date:11/2/2010

NEW YORK (November 2, 2010) -- For patients with the most common form of hepatitis C being treated for the first time, the addition of an investigational hepatitis Cspecific protease inhibitor called telaprevir to the current standard therapy markedly improved their sustained viral response (SVR or viral cure) rate.

The lead investigator reporting the results of the ADVANCE trial is Dr. Ira M. Jacobson, chief of the Division of Gastroenterology and Hepatology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and the Vincent Astor Distinguished Professor of Medicine at Weill Cornell Medical College. Dr. Jacobson presented these pivotal Phase III results today at the 61st Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

Dr. Jacobson noted that 75 percent of patients treated with a telaprevir-based combination regimen for 12 weeks, followed by 12 or 36 weeks of the standard therapy of pegylated-interferon alfa-2a and ribavirin alone, achieved a viral cure. This compared to 44 percent of people treated with 48 weeks of pegylated-interferon and ribavirin alone. In addition, new data from the study showed that 62 percent of African-Americans achieved a viral cure with the telaprevir-based regimen compared to 25 percent of African-Americans who were treated with pegylated-interferon and ribavirin alone. Additionally, 62 percent of patients with advanced liver fibrosis (cirrhosis or scarring of the liver) achieved a viral cure with the telaprevir regimen compared to 33 percent who were treated with pegylated-interferon and ribavirin alone.

"These groundbreaking data, showing sustained viral response in 75 percent of patients who received 12 weeks of telaprevir combination therapy, highlight telaprevir as a potential new therapy that, if approved by the FDA, could dramatically improve the future treatment of hepatitis C," says Dr. Jacobson, who is also a hepatologist and Medical Director the
'/>"/>

Contact: Linda Kamateh
lib9027@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New screening system for hepatitis C
2. Groundbreaking research to find vaccine for hepatitis C
3. 1 in 5 At-Risk U.S. Babies Doesnt Get Hepatitis B Vaccine
4. Vaccination, Prevention Is Beating Back Hepatitis
5. Bipartisan Capitol Hill Media Event: Health Experts, Lawmakers to Urge Federal Government to Fix the Funding Failure for Chronic Viral Hepatitis
6. Hepatitis C treatment less effective in urban minority patients
7. Researchers identify potential new target for treating hepatitis C
8. Donor kidneys from Hepatitis C patients needlessly denied to patients with that infection
9. Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer
10. New Drug Shows Promise for Curing Hepatitis C
11. Hepatitis C Tied to Higher Kidney Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... ultrasounds uncover antenatal hydronephrosis, or enlarged kidneys, the ... States. Many children with this abnormality are treated ... years of life with the hopes of preventing ... however, little evidence existed as to the benefits ... inconvenience for families. But a study published this ...
(Date:7/24/2014)... American air and missile defense radar market is estimated to ... a CAGR of 8.22% to reach $2.7 billion in 2020. ... and missile defense radar system. However, in the recent economic ... , Browse through the TOC of the North American air ... of the in-depth analysis provided. This report also provides a ...
(Date:7/24/2014)... composed of a single soul inhabiting two bodies." Poetic ... were made in heaven for each other can hurt ... observe that people talk and think about love in ... common themes that frame how we think about relationships. ... unity ("made for each other," "she,s my other half"); ...
(Date:7/24/2014)... 24, 2014 The National Resident ... launch of a new version of its smartphone app, ... PRISM, for applicants participating in NRMP’s Main Residency Match® ... track and organize program information during the interview process ... creating their rank order lists. Rank order lists ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 RxNetwork ... of prescription non-adherence at Cardinal Health RBC 2014 ... Utilizing familiar and user-friendly Mobile devices, RxNetwork is ... payers. , Already embraced by over 100 ... patients and caregivers through timely alerts and messages ...
Breaking Medicine News(10 mins):Health News:Continuous antibiotics not necessary for many children with common prenatal abnormality 2Health News:Continuous antibiotics not necessary for many children with common prenatal abnormality 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 2Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 4Health News:New research: When it hurts to think we were made for each other 2Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 2Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 3Health News:RxNetwork Brings the Next Generation Customer Care Connectivity to Pharmacies, Providers, and Patients 2
... have identified two genes believed to play a role in ... to better diagnosis and treatment of this increasingly common form ... or womb cancer, is the most common malignant cancer of ... of cases being detected has increased markedly, as has mortality. ...
... While studying an HIV protein that plays an essential ... Pittsburgh School of Medicine have discovered compounds that show ... drug discovery efforts have met with little success in ... factor, called Nef, because it lacks biochemical activity that ...
... how your eyes adjust during a blackout? When we go ... must quickly adjust. Vision scientists at Washington University School of ... allows the human eye to adapt to darkness very quickly. ... bright light. The discovery could contribute to better understanding ...
... treatments instead, study finds, , TUESDAY, Oct. 13 (HealthDay News) ... cancer are not turning to mastectomy as their first choice ... as lumpectomy, a new survey has found. , The survey, ... of the American Medical Association , also found that U.S. ...
... ... Support for the Nationwide Health Information Network. , ... Chantilly, VA (PRWEB) October 13, 2009 -- Agilex Technologies, Inc. , ... and public sectors , today announced the appointment of Melissa Chapman to the ...
... fastest-growing retailer of authentic nonfat frozen yogurt, announced it ... , to celebrate the favorite food of the fall ... Spice frozen yogurt, available at all Red Mango ... 13, through December 31, 2009. , (Photo: ...
Cached Medicine News:Health News:Genes behind increasingly common form of cancer identified 2Health News:Pitt researchers find candidates for new HIV drugs 2Health News:Researchers discover mechanism that helps humans see in bright and low light 2Health News:Researchers discover mechanism that helps humans see in bright and low light 3Health News:Mastectomy Not First Choice for Most Breast Cancer Patients 2Health News:Mastectomy Not First Choice for Most Breast Cancer Patients 3Health News:Agilex Technologies Hires Former HHS CIO Melissa Chapman to Lead Health Technology Programs 2Health News:Agilex Technologies Hires Former HHS CIO Melissa Chapman to Lead Health Technology Programs 3Health News:Discover Red Mango's New Seasonal Flavor: Pumpkin Spice 2
(Date:7/24/2014)... N.Y. , July 24, 2014  Kinex Pharmaceuticals ... FDA for the Company,s KX2-391 Ointment for the commencement ... This is the Company,s third IND to be allowed ... KX2-391 is a synthetic, orally active and ... tubulin polymerization. KX2-391 promotes the induction of p53, G2/M ...
(Date:7/24/2014)... , July 24, 2014 Consolidated Net ... Business Highlights   , India Business grew ... by 9.33% to Rs. 4,886.70 Mn Rest of World ... Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn ... , Glenmark Pharmaceuticals Limited, the research-led global ...
(Date:7/24/2014)... Boston Children,s Hospital,s Global Pediatric Summit + Awards, ... Tank" – a forum designed to give pediatric health ... product solution to a panel of acclaimed judges for ... the innovation and bring it to market. ... will be moderated by Daymond John of ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3
... MOUNTAIN VIEW, Calif., Nov. 7, 2011 Alexza Pharmaceuticals, ... results for the fiscal quarter ended September 30, 2011 ... the quarters ended September 30, 2011 and 2010, as ... the United States (GAAP), were $13.4 million and $0.6 ...
... LIBERTY, Mo. and DANBURY, Conn., Nov. 7, 2011 ... "Planet"), a privately held specialty pharmaceutical company focused on ... that it had completed an asset sale of ALLERGY ... ACQUISITION LLC, a New Jersey limited liability company. ...
Cached Medicine Technology:Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 2Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 3Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 4Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 5Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 6Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 7
Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....
This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption....
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... Myeloperoxidase IgG ELISA test system is intended ... IgG-class antibody to myeloperoxidase in human serum. ... used as an aid in the diagnosis ... elevated levels of anti-neutrophil cytoplasmic antibodies (ANCA). ...
Medicine Products: